iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Aarti Drugs Q4 PAT rises 7% YoY to Rs 55 cr

9 May 2022 , 04:14 PM

The companys consolidated net sales jumped 38.4% to Rs 694.27 crore in Q4 FY22 compared to Rs 501.75 in Q4 FY21. Profit before tax rose 8% year on year to Rs 70.5 crore in Q4 FY22. Total expenses were up by 43.2% year on year to Rs 626.73 crore in Q4 FY22. Cost of raw materials consumed stood at Rs 471.08 crore, rising by 56.3% year on year in the quarter ended 31 March 2022. On full year basis, the pharma company posted a 26.9% decline in net profit to Rs 205.04 crore despite a 15.5% increase in net sales to Rs 2,488.65 crore in FY22 over FY21. Aarti Drugs is primarily involved in manufacturing and marketing of active pharmaceutical ingredients (API), pharma intermediates and specialty chemicals. Shares of Aarti Drugs closed 0.15% lower to end at Rs 445 on the BSE. Powered by Capital Market – Live News

Related Tags

  • capital market
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.